BioCentury | Jun 20, 2020
Management Tracks

Nurix bolsters leadership; plus Lynch named Xilio chairman, Edgewise, BioXCel, Catabasis, Catalyst and more

...at Allergan plc, which AbbVie Inc. (NYSE:ABBV) in May for $63 billion. Rare diseases company Catabasis Pharmaceuticals Inc....
...clinical development at Merus N.V. (NASDAQ:MRUS). Robin Sawka, BioCentury Staff Nurix Therapeutics Inc. Xilio Therapeutics Inc. Edgewise Therapeutics BioXcel Therapeutics Inc. Catabasis Pharmaceuticals Inc. Catalyst...
BioCentury | Dec 11, 2019
Finance

Omega seeking broad swath of deal types for $438M sixth fund

...October, Omega named Deirdre Cunnane COO and general counsel; she was chief legal officer at Catabasis Pharmaceuticals Inc....
BioCentury | Jul 13, 2019
Finance

How crossover, insider support and big money correlated with performance across 1H19 IPOs

...A) 2/8/19 $6.5 NA $9.2 NA Biocept Inc. (NASDAQ:BIOC) (A) 2/8/19 $7.5 NA $20.9 NA Catabasis Pharmaceuticals Inc....
BioCentury | Feb 8, 2019
Financial News

Catabasis raises $20 million follow-on

...with each whole warrant exercisable at $6.25. Oppenheimer underwrote the offering. Catabasis Pharmaceuticals Inc. (NASDAQ:CATB), Cambridge, Mass. Shannon Lehnbeuter Catabasis Pharmaceuticals Inc....
BioCentury | Oct 9, 2018
Company News

Management tracks: Pfizer unveils Bourla’s team

...hired Ted Hibben as chief business officer of the neurology company. He was CBO at Catabasis Pharmaceuticals Inc....
BioCentury | Feb 16, 2018
Clinical News

Catabasis reports 60-week data for edasalonexent in DMD

...is a conjugate of salicylate and docosahexaenoic acid (DHA) that inhibits activated NF-kappa B (NF-kB). Catabasis Pharmaceuticals Inc....
...pharmacokinetics Status: Extension study data Milestone: Start Phase III (1H18); Phase III data (2020) Jaime De Leon CAT-1004 edasalonexent Catabasis Pharmaceuticals Inc. Nuclear...
BioCentury | Feb 13, 2018
Clinical News

Catabasis gains on 60-week DMD data

...a conjugate of salicylate and docosahexaenoic acid (DHA) that inhibits activated NF-kappa B (NF-kB). Jaime De Leon CAT-1004 edasalonexent Catabasis Pharmaceuticals Inc. Nuclear...
BioCentury | Oct 13, 2017
Regulation

Seeking surrogates

...new endpoints could join or replace dystrophin as acceptable primary surrogate endpoints. On Oct. 4, Catabasis Pharmaceuticals Inc....
...the change,” she said. Companies and Institutions Mentioned BioMarin Pharmaceutical Inc. (NASDAQ:BMRN), San Rafael, Calif. Catabasis Pharmaceuticals Inc....
BioCentury | Oct 10, 2017
Distillery Therapeutics

Neurology

...Nippon Zoki Pharmaceutical Co. Ltd. have the compound in preclinical testing to treat disc degeneration. Catabasis Pharmaceuticals Inc....
BioCentury | Oct 6, 2017
Clinical News

Catabasis' DMD candidate slows disease progression in Phase I/II

...for registration, but said the company is discussing the program with regulators around the world. Catabasis Pharmaceuticals Inc....
...of life (QOL) and pharmacokinetics Status: Additional Phase I/II data Milestone: Start Phase III (1H18) Mary Romeo CAT-1004 edasalonexent Catabasis Pharmaceuticals Inc. Nuclear...
Items per page:
1 - 10 of 61
BioCentury | Jun 20, 2020
Management Tracks

Nurix bolsters leadership; plus Lynch named Xilio chairman, Edgewise, BioXCel, Catabasis, Catalyst and more

...at Allergan plc, which AbbVie Inc. (NYSE:ABBV) in May for $63 billion. Rare diseases company Catabasis Pharmaceuticals Inc....
...clinical development at Merus N.V. (NASDAQ:MRUS). Robin Sawka, BioCentury Staff Nurix Therapeutics Inc. Xilio Therapeutics Inc. Edgewise Therapeutics BioXcel Therapeutics Inc. Catabasis Pharmaceuticals Inc. Catalyst...
BioCentury | Dec 11, 2019
Finance

Omega seeking broad swath of deal types for $438M sixth fund

...October, Omega named Deirdre Cunnane COO and general counsel; she was chief legal officer at Catabasis Pharmaceuticals Inc....
BioCentury | Jul 13, 2019
Finance

How crossover, insider support and big money correlated with performance across 1H19 IPOs

...A) 2/8/19 $6.5 NA $9.2 NA Biocept Inc. (NASDAQ:BIOC) (A) 2/8/19 $7.5 NA $20.9 NA Catabasis Pharmaceuticals Inc....
BioCentury | Feb 8, 2019
Financial News

Catabasis raises $20 million follow-on

...with each whole warrant exercisable at $6.25. Oppenheimer underwrote the offering. Catabasis Pharmaceuticals Inc. (NASDAQ:CATB), Cambridge, Mass. Shannon Lehnbeuter Catabasis Pharmaceuticals Inc....
BioCentury | Oct 9, 2018
Company News

Management tracks: Pfizer unveils Bourla’s team

...hired Ted Hibben as chief business officer of the neurology company. He was CBO at Catabasis Pharmaceuticals Inc....
BioCentury | Feb 16, 2018
Clinical News

Catabasis reports 60-week data for edasalonexent in DMD

...is a conjugate of salicylate and docosahexaenoic acid (DHA) that inhibits activated NF-kappa B (NF-kB). Catabasis Pharmaceuticals Inc....
...pharmacokinetics Status: Extension study data Milestone: Start Phase III (1H18); Phase III data (2020) Jaime De Leon CAT-1004 edasalonexent Catabasis Pharmaceuticals Inc. Nuclear...
BioCentury | Feb 13, 2018
Clinical News

Catabasis gains on 60-week DMD data

...a conjugate of salicylate and docosahexaenoic acid (DHA) that inhibits activated NF-kappa B (NF-kB). Jaime De Leon CAT-1004 edasalonexent Catabasis Pharmaceuticals Inc. Nuclear...
BioCentury | Oct 13, 2017
Regulation

Seeking surrogates

...new endpoints could join or replace dystrophin as acceptable primary surrogate endpoints. On Oct. 4, Catabasis Pharmaceuticals Inc....
...the change,” she said. Companies and Institutions Mentioned BioMarin Pharmaceutical Inc. (NASDAQ:BMRN), San Rafael, Calif. Catabasis Pharmaceuticals Inc....
BioCentury | Oct 10, 2017
Distillery Therapeutics

Neurology

...Nippon Zoki Pharmaceutical Co. Ltd. have the compound in preclinical testing to treat disc degeneration. Catabasis Pharmaceuticals Inc....
BioCentury | Oct 6, 2017
Clinical News

Catabasis' DMD candidate slows disease progression in Phase I/II

...for registration, but said the company is discussing the program with regulators around the world. Catabasis Pharmaceuticals Inc....
...of life (QOL) and pharmacokinetics Status: Additional Phase I/II data Milestone: Start Phase III (1H18) Mary Romeo CAT-1004 edasalonexent Catabasis Pharmaceuticals Inc. Nuclear...
Items per page:
1 - 10 of 61